Recent Company News

• 02:18 PM ET Nov 06, 2025
  

  FDA awards second batch of CNPVs, six more including two obesity drugs

• 04:56 AM ET Oct 24, 2025
  

  Chugai Pharmaceutical to buy Renalys Pharma for ¥15.00B in cash plus amount reflecting price adjustment; to pay seller up to ¥16.00B in milestone payments (¥6935.0000, 0)

• 04:43 AM ET Oct 24, 2025
  

  StreetAccount Metrics Recap - Chugai Pharmaceutical Q3 Earnings (¥6935.0000, 0)

• 04:19 AM ET Oct 24, 2025
  

  Chugai Pharmaceutical reports Q3 core net income attributable ¥126.5B vs FactSet ¥118.02B (¥6935.0000, 0)

• 04:17 AM ET Oct 21, 2025
  

  Chugai Pharmaceutical reports Alecensa median overall survival of 81.1 months in ALK-positive non-small cell lung cancer (¥7158.0000, 0)

• 07:33 AM ET Oct 17, 2025
  

  Rani Therapeutics announces up to $1.085B collaboration with Chugai Pharmaceutical, concurrent oversubscribed $60.3M financing ($0.47, 0.00)

• 08:10 AM ET Oct 15, 2025
  

  Chugai Pharmaceutical notes Eli Lilly reports topline results from phase 3 ACHIEVE-2 and ACHIEVE-5 trials of orforglipron (¥7025.0000, 0)

• 07:01 PM ET Oct 14, 2025
  

  Eli Lilly to launch new obesity drug Retatrutide for patients with severe cases as soon as 2027 - Nikkei ($812.35, 0.00)

• 10:51 PM ET Oct 13, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 04:09 AM ET Oct 10, 2025
  

  Roche gives Chugai Pharmaceutical exclusive rights to develop and market CT-388 in Japan (¥7479.0000, 0)